이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Chimerix 대차 대조표 상태

재무 상태 기준 확인 6/6

Chimerix 의 총 주주 지분은 $174.1M 이고 총 부채는 $0.0, 이는 부채 대 자기자본 비율을 0% 로 가져옵니다. 총자산과 총부채는 각각 $194.0M 및 $19.9M 입니다.

주요 정보

부채 비율

US$0

부채

이자 보상 비율	n/a
현금	US$159.03m
주식	US$174.10m
총 부채	US$19.94m
총 자산	US$194.04m

최근 재무 상태 업데이트

Recent updates

Chimerix: Advancement For Rare Brain Cancer Drug Targeting Specific Mutation

Aug 23

Here's Why We're Watching Chimerix's (NASDAQ:CMRX) Cash Burn Situation

Jul 20

Chimerix: Down But Not Out

Jun 06

Chimerix: Searching For Clarity

Jan 05

Does Chimerix (NASDAQ:CMRX) Have A Healthy Balance Sheet?

Dec 24

Is Chimerix (NASDAQ:CMRX) A Risky Investment?

Sep 16

Does Chimerix (NASDAQ:CMRX) Have A Healthy Balance Sheet?

Jun 08

Chimerix gets FDA approval for TEMBEXA for the treatment of smallpox

Jun 04

Chimerix, Inc. (NASDAQ:CMRX): Are Analysts Optimistic?

May 13

Chimerix Investor Presentation - Slideshow

May 08

Chimerix expands oncology program with acquisition of Oncoceutics, shares up 10%

Jan 08

Who Has Been Buying Chimerix, Inc. (NASDAQ:CMRX) Shares?

Jan 01

Chimerix rises 9.1% premarket after FDA accepts NDA for smallpox countermeasure

Dec 07

Chimerix (NASDAQ:CMRX) Is In A Good Position To Deliver On Growth Plans

Dec 05

Chimerix, Inc. 2020 Q3 - Results - Earnings Call Presentation

Nov 08

Chimerix EPS misses by $0.01, beats on revenue

Nov 05

재무 상태 분석

단기부채: CMRX 의 단기 자산 ( $163.0M )이 단기 부채( $18.9M ).

장기 부채: CMRX 의 단기 자산( $163.0M )이 장기 부채( $1.0M ).

부채 대 자본 내역 및 분석

부채 수준: CMRX 부채가 없습니다.

부채 감소: CMRX 5년 전에 부채가 없었습니다.

대차 대조표

현금 런웨이 분석

과거에 평균적으로 적자를 기록했던 기업의 경우, 최소 1년 이상의 현금 유동성을 보유하고 있는지 평가합니다.

안정적인 현금 활주로: CMRX 현재 무료 현금 흐름을 기준으로 1년 이상 충분한 현금 활주로를 보유하고 있습니다.

예측 현금 활주로: CMRX 2.6 1.8 2.6 % 매년.

Chimerix 대차 대조표 상태

재무 상태 기준 확인 6/6

주요 정보

최근 재무 상태 업데이트

Here's Why We're Watching Chimerix's (NASDAQ:CMRX) Cash Burn Situation

Does Chimerix (NASDAQ:CMRX) Have A Healthy Balance Sheet?

Is Chimerix (NASDAQ:CMRX) A Risky Investment?

Does Chimerix (NASDAQ:CMRX) Have A Healthy Balance Sheet?

Chimerix (NASDAQ:CMRX) Is In A Good Position To Deliver On Growth Plans

Recent updates

Consensus revenue estimates fall by 36%

First quarter 2024 earnings released: US$0.24 loss per share (vs US$0.24 loss in 1Q 2023)

Price target decreased by 8.7% to US$7.00

Chimerix, Inc., Annual General Meeting, Jun 20, 2024

Chimerix, Inc. to Report Q1, 2024 Results on May 01, 2024

Chimerix Appoints Marc D. Kozin to Board of Directors

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Chimerix, Inc. to Report Q4, 2023 Results on Feb 29, 2024

Chimerix Announces Board Changes

Chimerix, Inc. Promotes Michelle Laspaluto to the Position of Chief Financial Officer

Chimerix, Inc. Appoints Michelle Laspaluto to Chief Financial Officer

Chimerix, Inc. Appoints Thomas Riga as Chief Operating and Commercial Officer

Consensus revenue estimates fall by 22%

New minor risk - Profitability

Third quarter 2023 earnings released: US$0.27 loss per share (vs US$2.75 profit in 3Q 2022)

Chimerix, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Chimerix Announces Data Highlighting Clinical Efficacy and Molecular Mechanisms of Response to Onc201 Treatment of H3 K27m-Mutant Diffuse Midline Gliomas Published in Cancer Discovery

Consensus revenue estimates decrease by 48%, EPS upgraded

New minor risk - Market cap size

Price target decreased by 8.3% to US$7.33

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Chimerix, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Chimerix, Inc. Announces Executive Changes, Effective on August 1, 2023

Chimerix, Inc.(NasdaqGM:CMRX) dropped from Russell 2000 Growth Index

CEO, President & Director recently bought US$98k worth of stock

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Full year 2022 earnings: Revenues and EPS in line with analyst expectations

Insufficient new directors

Chimerix, Inc. Announces Successful Launch of ONC201 Phase 3 Action Study

Price target decreased to US$8.00

Rubric Capital Management Sends Letter to Chimerix

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Emergent BioSolutions Inc. (NYSE:EBS) completed the acquisition of Exclusive Worldwide Rights to Brincidofovir, Including TEMBEXA® from Chimerix, Inc. (NasdaqGM:CMRX) for approximately $370 million.

Price target decreased to US$8.00

Chief Business Officer exercised options to buy US$111k worth of stock.

Chimerix: Advancement For Rare Brain Cancer Drug Targeting Specific Mutation

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Chimerix, Inc. to Report Q2, 2022 Results on Aug 08, 2022

Here's Why We're Watching Chimerix's (NASDAQ:CMRX) Cash Burn Situation

Chimerix: Down But Not Out

Price target decreased to US$8.20

Emergent BioSolutions Inc. (NYSE:EBS) entered into an agreement to acquire Exclusive Worldwide Rights to Brincidofovir, Including TEMBEXA® from Chimerix, Inc. (NasdaqGM:CMRX) for approximately $340 million.

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Chimerix, Inc. to Report Q1, 2022 Results on May 16, 2022

No longer forecast to breakeven

Consensus EPS estimates fall by 23%

Consensus estimates of losses per share improve by 44%

No longer forecast to breakeven

No longer forecast to breakeven

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Chimerix, Inc. to Report Q4, 2021 Results on Mar 01, 2022

Chimerix, in Collaboration with the Rapidly Emerging Antiviral Drug Development Initiative Announces Late-Breaking Oral Presentation At International Conference on Antiviral Research

Chimerix, Inc. Announces Publication of Positive ONC201 Data from Phase 2 Study in Neuroendocrine Tumors in Clinical Cancer Research

Chimerix: Searching For Clarity

Forecast to breakeven in 2024

Does Chimerix (NASDAQ:CMRX) Have A Healthy Balance Sheet?

Third quarter 2021 earnings released: US$0.21 loss per share (vs US$0.18 loss in 3Q 2020)

Is Chimerix (NASDAQ:CMRX) A Risky Investment?

Consensus revenue estimates fall to US$27.8m

Independent Director recently bought US$78k worth of stock

Does Chimerix (NASDAQ:CMRX) Have A Healthy Balance Sheet?

Chimerix Receives U.S. Food and Drug Administration Approval for TEMBEXA® (brincidofovir) for the Treatment of Smallpox

Consensus forecasts updated

Chimerix gets FDA approval for TEMBEXA for the treatment of smallpox

Forecast to breakeven in 2024

Chimerix, Inc. (NASDAQ:CMRX): Are Analysts Optimistic?

Chimerix Investor Presentation - Slideshow

Consensus revenue estimates fall to US$43.6m

First quarter 2021 earnings released: US$1.22 loss per share (vs US$0.17 loss in 1Q 2020)

Full year 2020 earnings released: US$0.70 loss per share (vs US$2.03 loss in FY 2019)